3 documents

Read All
07:00 , Sep 23, 2013 |  BioCentury  |  Emerging Company Profile

Tube: Potent payloads

The potency of Tube Pharmaceuticals GmbH 's tubulysin toxin as a conjugate payload could allow the company to target resistant cancers. Tube is developing a polymer-tubulysin conjugate for solid tumors and has out-licensed the toxin...
Read More
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

Cream skimming

Cream skimming Wellington Partners expects its fourth life science fund will be about 54% larger than the prior fund. And with less and less venture money available in Europe, the firm should have its pick...
Read More
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Vion, University of Innsbruck, Austria Wirtschaftsservice GmbH deal

VION exercised an option under a 2003 deal to exclusively license preclinical heterocyclic hydrazone compounds to treat cancer from inventors at the university and from Austria Wirtschaftsservice, a technology transfer bank. The researchers and the...
Read More